FCMI
INFI

Foresite Capital Management III’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Foresite Capital Management III’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-738,896
Closed -$1.16M – 27
2017
Q2 		$1.16M Buy
+738,896
New +$1.43M 0.38% 19

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Foresite Capital Management III's INFI Position: Q3 2017 in Review

Foresite Capital Management III sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2017, closing a stake of 738,896 shares — an estimated $1.16M sold.

Foresite Capital Management III first reported a position in INFI in Q2 2017 and held it in 1 quarter. The position peaked at $1.16M in Q2 2017. 63 funds tracked by Wall St. Rank hold INFI as of Q3 2017.

  • Foresite Capital Management III reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Foresite Capital Management III sold 738,896 Infinity Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.16M.
  • Foresite Capital Management III first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Foresite Capital Management III's Infinity Pharmaceuticals, Inc. position peaked at $1.16M in Q2 2017.
  • 63 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2017.

Based on Foresite Capital Management III's 13F filing for Q3 2017, filed 13 Nov 2017.